#regulatory-approvals

#regulatory-approvals

Medtronic ( NYSE: MDT) delivered its strongest enterprise revenue growth in 10 quarters, posting 8.7% reported growth (6.0% organic) for Q3 fiscal 2026. Cardiac Ablation Drives Outperformance The Cardiovascular Portfolio led the quarter with 13.8% reported growth, powered by an exceptional 80% surge in Cardiac Ablation Solutions. U.S. cardiac ablation revenue exploded 137%, driven by the company's pulsed field ablation (PFA) portfolio. Cardiac Rhythm & Heart Failure revenue reached $1.86 billion, up 17%, while Diabetes posted 8.3% organic growth to $796 million.

And while robotaxi rival Waymo recently partnered with DoorDash to test food deliveries with driverless cars, Levinson said that Zoox is "laser focused" on moving people around cities, an addressable market he sees as being "just profoundly huge." That directive has come "all the way from the very top" at Amazon, he added, despite the retailer's significant interest in driverless package delivery.